Business Context and Reporting Period
This Form 8-K was filed by Stereotaxis, Inc. on March 16, 2005, reporting events that occurred on March 14 and 15, 2005. The filing serves as a Regulation FD disclosure regarding the commencement of commercial procedures in Europe.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on operational milestones and product commercialization rather than financial performance data.
Material Changes
The primary material change reported is the execution of the first commercial procedures in Europe utilizing the Stereotaxis NIOBE system. These procedures integrated the following products, which recently received CE Marking Authorization:
- Celsius RMT Ablation catheter
- NaviStar RMT Mapping and Ablation Catheter
- CARTO RMT Navigation and Ablation System
These products represent the first commercialization efforts under Stereotaxis's strategic alliance with Biosense Webster, a Johnson & Johnson company.
Outlook and Management Commentary
Management believes that this family of advanced electrophysiology ablation and mapping catheters, combined with the CARTO mapping and localization system, will significantly enhance the clinical utility and functionality of the Stereotaxis NIOBE system within the electrophysiology field. The filing notes that the information is furnished pursuant to Item 7.01 and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the scope and volume of commercial procedures performed in Europe following the March 14-15, 2005 dates.
- Confirm the status of the strategic alliance with Biosense Webster and future product rollout timelines.
- Review subsequent financial reports to assess the revenue impact of the CE Marking Authorization and European market entry.
- Monitor regulatory updates regarding the NIOBE system and associated catheters in other global markets.